Cocrystal Pharma, Inc. (COCP): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On August 12, 2026, the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed Carol L. B
- Person
- Carol L. Brosgart
- Title
- director
- Action
- appointed
- Effective
- August 12, 2026
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The disclosure confirms a new director appointment effective immediately, with no related-party transactions requiring Item 404(a) disclosure.
Market read
This is a routine governance update. It may slightly influence sentiment, but it does not introduce new financial guidance, clinical, regulatory, or deal catalysts.
What to watch
Check for any concurrent committee assignments, compensation details, or follow-on filings (proxy/other 8-K items) that could make the appointment more material than it appears here.
Background
The company filed an SEC Form 8-K under Item 5.02 for director/officer changes and compensatory arrangements.
Ticker impact
Cocrystal Pharma appointed Carol L. Brosgart as a director effective immediately, disclosed in its Aug. 12, 2026 8-K.
Low likelihood of a sustained price move solely from this disclosure; any reaction is likely modest and short-lived.
The filing discloses a new director appointment without related-party transactions or additional operational/financial commitments, so incremental information is limited.
Market effects
Minimal sector read-through; this is company-specific governance news.
No clear regional spillover expected.
No direct global market relevance indicated.
Counterpoint
The appointment could be a precursor to broader strategic changes, but the 8-K provides no such details, so traders may be overreacting if they extrapolate.
Key entities
- issuerCocrystal Pharma, Inc.
Nasdaq-listed company filing the 8-K for a director appointment.
- personCarol L. Brosgart
Appointed as a director effective immediately on Aug. 12, 2026.
- officerJames Martin
CFO signing the filing.
